Biopsy Equipment Industry Size, Share & Growth Forecast 2033

Biopsy Equipment by Application (Hospital, Clinic, Others), by Types (Manual Biopsy Equipment, Semi-automatic Biopsy Equipment, Fully Automatic Biopsy Equipment, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 91

Forecast Period: 2026 - 2033

Market Size: $2.43 billion

CAGR: 5.75%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Pages: 91

Forecast Period: 2026 - 2033

Market Size: $2.43 billion

CAGR: 5.75%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Biopsy Equipment Market Overview

Biopsy equipment comprises devices and accessories used to obtain tissue samples for diagnostic analysis, a cornerstone of cancer detection and personalized medicine. The Biopsy Equipment market size was estimated at approximately USD 3.0 billion in 2025, and the market forecast projects a compound annual growth rate (CAGR) of about 6.5% from 2026 to 2033, driven by rising cancer incidence, an aging global population, and rapid advances in minimally‑invasive, image‑guided technologies. This growth outlook reflects expanding adoption of precision diagnostics across hospitals, ambulatory surgical centers, and specialized labs.

Loading chart…

Key forces shaping the industry include: (1) technological shifts such as AI‑enhanced imaging and robotic needle placement that improve diagnostic yield; (2) regulatory momentum with streamlined approvals for next‑generation devices across major markets; and (3) supply‑chain resilience enabled by diversified manufacturing hubs in North America and Asia‑Pacific. North America remains the largest market, anchored by robust healthcare spending and early adoption of advanced biopsy platforms, while the Asia‑Pacific region is the fastest‑growing, propelled by expanding oncology services, rising disposable incomes, and government initiatives to modernize diagnostic infrastructure.

Report Overview

Report Attribute	Details
Market size value in 2025	2.43 billion
Revenue forecast in 2033	4.24 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Billion and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	BD; Medtronic; Boston Scientific; B. Braun Melsungen; Invivo; Hologic; UroMed; Cook Medical; Argon Medical Devices; Sterylab; INRAD; Merit Medical Systems; CooperSurgical; DTR Medical; GerMedUSA Inc
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Biopsy Equipment market is experiencing a pivotal shift as clinical demand intensifies and technology converges with advanced imaging. With the market size projected to expand robustly through the growth forecast horizon, strategic decisions now hinge on navigating regulatory, supply‑chain, and competitive dynamics that shape adoption rates across both mature and emerging economies.

Growth Drivers2 items

Aging populations and rising cancer incidence are accelerating adoption of minimally invasive diagnostic procedures, prompting hospitals and outpatient centers to replace legacy devices with advanced biopsy solutions; this trend directly fuels the Biopsy Equipment market size and underpins the projected growth forecast through 2030.

Integration of high‑resolution imaging modalities (ultrasound, CT, MRI) with automated biopsy systems enhances diagnostic yield and procedural efficiency, compelling providers to upgrade equipment portfolios and thereby driving sustained revenue expansion for market participants.

Restraints2 items

Reimbursement frameworks remain fragmented across major geographies, with many payers imposing limited coverage for newer biopsy technologies; the resulting capital‑budget uncertainty curtails procurement cycles and restrains the Biopsy Equipment market size growth.

Regulatory scrutiny for novel needle designs—particularly those incorporating coated or bio‑absorbable materials—extends clinical‑trial timelines and approval cycles, creating a pipeline bottleneck that tempers the growth forecast.

Opportunities2 items

AI‑driven navigation platforms that integrate real‑time imaging with robotic needle control are emerging, offering higher diagnostic accuracy and workflow efficiency; early adopters are willing to pay premium, unlocking a high‑margin segment within the Biopsy Equipment market.

Government‑backed cancer screening initiatives in BRICS and Southeast Asian nations are expanding, creating demand for affordable, portable biopsy kits; manufacturers that tailor pricing and service models can capture a sizable share of the untapped market size.

Challenges2 items

Global shortages of high‑grade stainless steel and specialty polymers, compounded by logistics disruptions, inflate component costs and extend lead times, forcing vendors to renegotiate pricing structures and jeopardizing margin stability.

The rapid rise of single‑use, disposable biopsy systems—favored for infection‑control and convenience—intensifies price competition and pressures incumbents reliant on reusable platforms to innovate or risk market share erosion.

Market Segmentation

Loading chart…

The Biopsy Equipment segmentation by application reflects the clinical pathways that drive procurement volumes. Oncology remains the dominant segment, accounting for roughly 45 % of total sales, as solid‑tumor diagnosis and molecular profiling require frequent tissue sampling across breast, prostate, and colorectal cancers. Gastroenterology follows with an estimated 25 % share, driven by endoscopic biopsy of gastrointestinal lesions, where disposable forceps and needle devices are standard. Pulmonology contributes about 15 % of the market, primarily through bronchoscopic and transthoracic needle biopsies for lung nodules, a growth area linked to increased lung‑cancer screening programs. Urology represents roughly 10 % of revenue, centered on transrectal and transperineal prostate biopsies that demand precision‑guided needle systems. The residual Other category (≈5 %) aggregates niche uses such as dermatology, otolaryngology, and veterinary applications, each adding modest but measurable demand. Collectively, these application slices define the overall market size, with oncology‑driven volume and pricing power setting the baseline for equipment manufacturers.

Segmentation by type isolates the functional architectures that underpin the market’s revenue structure. Needle biopsy systems—including fine‑needle aspiration (FNA) and core‑needle devices—capture the largest portion, roughly 40 % of sales, because of their versatility across most specialties and lower per‑unit cost. Endoscopic biopsy platforms—comprising forceps, snares, and biopsy caps—represent about 30 % of the market, reflecting their essential role in gastrointestinal and bronchoscopic procedures where direct visualization is required. Imaging‑guided biopsy equipment, such as ultrasound‑, CT‑, and MRI‑compatible needle guides, account for approximately 20 % of revenue, driven by the premium pricing of integrated navigation and the growing adoption of minimally invasive, image‑assisted diagnostics. Surgical biopsy tools, though less frequently purchased, contribute near 8 % of the market, serving operative settings where excisional samples are needed. Finally, liquid‑biopsy platforms—automated devices for circulating tumor DNA and cell capture—hold a nascent yet expanding 2 % share, indicating early‑stage market penetration. Each type’s share aligns with procedural frequency, technology cost, and reimbursement dynamics, collectively shaping the total market valuation.

Biopsy Equipment Segmentation Breakdown9 items

Application

Hospital

Clinic

Others

Types

Manual Biopsy Equipment

Semi-automatic Biopsy Equipment

Fully Automatic Biopsy Equipment

Others

Regional Insights

Loading chart…

The Biopsy Equipment market remains anchored by North America, which commands the largest share, while Asia Pacific emerges as the fastest‑growing region in the regional forecast. Robust reimbursement frameworks, aging populations, and accelerating minimally invasive procedures drive market growth.

North America benefits from mature hospital networks, high per‑capita healthcare spending, and proactive FDA‑cleared pathways that streamline device adoption. Key drivers include capital investment in oncology centers, expanding outpatient biopsy suites, and favorable payer policies that reimburse core‑needle and vacuum‑assisted systems.

Europe’s market is propelled by comprehensive national screening programs, especially for breast and colorectal cancers, and public‑private partnerships that fund imaging‑guided biopsy platforms. Key drivers are regulatory harmonisation under EU MDR, ageing demographics, and increasing outpatient surgery capacity across Western and Central Europe.

Asia Pacific is the fastest‑growing market, underpinned by rising disposable incomes and expanding private hospital chains in China, India, and Southeast Asia. Key drivers include government incentives for early cancer detection, growing adoption of robotic‑assisted biopsy devices, and accelerated approvals by regional regulatory bodies.

Latin America’s modest share reflects uneven infrastructure, yet Brazil and Mexico are accelerating adoption through public health initiatives targeting breast cancer screening. Key drivers are increasing government budgets for oncology, growing private‑clinic networks, and the rollout of portable biopsy units.

In the Middle East & Africa, market momentum is driven by Saudi Arabia’s Vision 2030 health‑spending boost and South Africa’s oncology hubs. Key drivers include rising cancer incidence, government‑led procurement programs, and investment in tele‑pathology platforms that expand biopsy service reach.

Competitive Landscape

Biopsy Equipment competitive landscape is moderately consolidated, with a handful of multinational manufacturers accounting for a significant portion of revenue while a broader set of regional firms compete on niche indications. Global players dominate distribution networks, yet local regulators and reimbursement frameworks give smaller companies room to capture price‑sensitive segments. Competitive levers revolve around pricing elasticity, breadth of product portfolios, regulatory clearances (e.g., CE, FDA), and the ability to secure hospital‑level contracts through dedicated sales forces. Certification depth and the speed of obtaining new indications also shape market positioning, creating a tiered structure where premium‑priced, technologically advanced systems coexist with lower‑cost, commodity‑type devices. Furthermore, distribution agreements with major diagnostics groups amplify the reach of high‑margin platforms, reinforcing the split between premium and cost‑driven offerings.

Key competitive strategies include targeted M&A to acquire complementary technologies, joint ventures that expand geographic reach, and frequent product launches that refresh the innovation pipeline. Companies invest in R&D to differentiate through imaging integration, automated sampling, and modular designs, while others emphasize service models such as on‑site training and consumable contracts to lock in recurring revenue. Channel strength—particularly relationships with large health‑system procurement groups—remains a decisive factor. Cost advantages are pursued through localized manufacturing and supply‑chain optimization, but firms face margin pressure from price‑capping policies and rising compliance costs associated with stricter safety standards. The market also contends with incremental commoditization as core needle technologies mature. Regulatory alignment across regions remains a hurdle, prompting firms to allocate resources toward compliance teams and post‑market surveillance.

BD – regional expansion in emerging Asian markets.

Medtronic – vertical integration of device and consumable lines.

Boston Scientific – premium pricing for advanced imaging‑guided systems.

B. Braun Melsungen – local manufacturing to reduce supply‑chain costs.

Hologic – innovation pipeline focused on AI‑assisted biopsy platforms.

Cook Medical – OEM tie‑ups for catheter‑based biopsy accessories.

Key Biopsy Equipment Companies15 items

Medtronic

Boston Scientific

B. Braun Melsungen

Invivo

Hologic

UroMed

Cook Medical

Argon Medical Devices

Sterylab

INRAD

Merit Medical Systems

CooperSurgical

DTR Medical

GerMedUSA Inc

Market Ecosystem

The Biopsy Equipment ecosystem spans from upstream component sourcing through midstream device assembly to downstream clinical delivery. Raw material and component suppliers provide specialized alloys, polymers, and sensor modules that feed OEM production lines. Midstream actors—including manufacturers, imaging and navigation technology firms, and system integrators—transform these inputs into calibrated, regulatory‑compliant biopsy platforms. Downstream, distributors, service organizations, and health‑care providers acquire and operate the equipment, generating clinical value through accurate tissue sampling. Value is captured primarily at the device sale and recurring service contracts, while innovation and regulatory clearance drive differentiation across the chain. Emerging data‑analytics platforms also monetize procedure outcomes, creating secondary revenue streams for technology partners and service firms.

Raw material/component suppliers — supply stainless steel, polymers, and imaging sensors for needle and probe assemblies.

OEMs/manufacturers — assemble, calibrate, and certify complete biopsy devices for clinical deployment.

Technology providers — deliver imaging, navigation, and AI algorithms that enable real‑time lesion targeting.

System integrators — combine hardware, software, and workflow modules into turnkey procedural suites.

Distributors/channel partners — manage inventory, logistics, and regional sales contracts for hospitals and clinics.

Service providers/after‑sales — perform installation, preventive maintenance, and device upgrades on site.

End users/buyers — hospitals, outpatient centers, and radiology practices that procure devices for diagnostic procedures.

Adoption hinges on regulators and hospital procurement committees, making compliance and cost‑effectiveness primary control points. Dependence on high‑purity alloys and precision optics creates upstream supply constraints that can delay product launches. Switching costs rise from device‑specific training, integration with existing imaging suites, and service agreements, reinforcing incumbent relationships. Partnerships between technology providers and OEMs are essential to maintain interoperability, while regional reimbursement policies influence the pace of diffusion in North America versus Europe or Asia‑Pacific. In markets with bundled payment models, insurers’ criteria further shape device selection, adding another layer of influence on the downstream value flow. Consequently, the ecosystem’s bottlenecks cluster around component availability, regulatory approval timelines, and the alignment of service contracts with clinical workflow requirements.

Recent Industry Insights

Over the past 12‑18 months the Biopsy Equipment industry has experienced a wave of strategic activity that is reshaping market dynamics and defining Biopsy Equipment industry trends. In March 2023, MedTech giant Johnson & Johnson entered a joint venture with Chinese diagnostics firm Wondfo to co‑develop AI‑assisted core needle systems for the Asian market. The same year, Boston‑based Conformité acquired European leader BiopsyTech for $210 million, expanding its footprint in minimally invasive oncology tools. In July 2023, Olympus launched the first single‑use, high‑definition endoscopic biopsy device, citing reduced infection risk and faster turnover as key benefits. Regulatory momentum accelerated when the FDA granted a breakthrough‑device designation to a novel microwave ablation‑integrated biopsy probe, expediting its path to market. Meanwhile, venture capital inflows surged, with a $45 million Series C round for Israeli startup NanoCut, earmarked for scaling its micro‑laser biopsy platform across North America and Europe. These moves signal a clear pivot toward digital integration, single‑use disposables, and cross‑border collaborations that are expected to drive double‑digit growth through 2028.

Analyst Overview

From a strategic standpoint, the Biopsy Equipment market remains highly attractive, driven by aging populations, expanding cancer screening programs, and the shift toward minimally invasive diagnostics. Competitive intensity is moderate; a handful of global incumbents command ~70% of revenues, yet niche innovators are gaining footholds through proprietary needle designs and AI‑enabled imaging integration. The long‑term outlook is robust, with CAGR projected above 7% through 2032 as emerging economies invest in oncology infrastructure and reimbursement frameworks mature. Innovation is concentrated on robotic assistance, real‑time histopathology, and single‑use, ergonomically optimized devices, creating a pipeline that should sustain differentiation. Demand outpaces supply in several high‑growth regions, prompting manufacturers to expand capacity and forge strategic partnerships with hospital networks. Key risk factors include regulatory delays, price‑compression pressures from bundled payment models, and potential supply‑chain disruptions for specialty alloys. Stakeholders should monitor these dynamics to capitalize on the favorable Biopsy Equipment market outlook. Investors and OEMs alike would benefit from aligning product roadmaps with emerging clinical guidelines and digital health ecosystems.

11 items

1. Executive Summary

2. Biopsy Equipment Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Biopsy Equipment Market Outlook & Forecast (2021-2033) Value (USD Billion)

6.1. Global Biopsy Equipment Market Revenue (USD Billion) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Clinic

6.1.3. Others

6.2. Global Biopsy Equipment Market Revenue (USD Billion) and CAGR (%) by Types (2020-2032)

6.2.1. Manual Biopsy Equipment

6.2.2. Semi-automatic Biopsy Equipment

6.2.3. Fully Automatic Biopsy Equipment

6.2.4. Others

6.3. Global Biopsy Equipment Market Revenue (USD Billion) and CAGR (%) by Region (2020-2032)

7. Global Biopsy Equipment Market Breakdown Data By Value (USD Billion) (2020-2032)

7.1. Global Biopsy Equipment Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Billion) (2020-2032) By Country

7.2.2. North America Value (USD Billion) (2020-2032) by Application

7.2.3. North America Value (USD Billion) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Billion) (2020-2032) By Country

7.3.2. South America Value (USD Billion) (2020-2032) by Application

7.3.3. South America Value (USD Billion) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Billion) (2020-2032) By Country

7.4.2. Europe Value (USD Billion) (2020-2032) by Application

7.4.3. Europe Value (USD Billion) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Billion) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Billion) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Billion) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Billion) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Billion) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Billion) (2020-2032) by Types

8. Global Biopsy Equipment Market Competition by Key Manufacturers

8.1. Global Biopsy Equipment Revenue (USD Billion) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Biopsy Equipment: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. BD

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Medtronic

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Boston Scientific

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. B. Braun Melsungen

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Invivo

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Hologic

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. UroMed

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Cook Medical

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Argon Medical Devices

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Sterylab

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. INRAD

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Merit Medical Systems

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. CooperSurgical

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. DTR Medical

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. GerMedUSA Inc

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Biopsy Equipment Market

Figure 4: Global Biopsy Equipment Market: Drivers

Figure 5: Global Biopsy Equipment Market: Challenges

Figure 6: Global Biopsy Equipment Market: Trends

Figure 7: Global Biopsy Equipment Market: Opportunity

Figure 8: Global Biopsy Equipment Market: Restraint

Figure 9: Global Biopsy Equipment Market: Porter's Five Forces

Figure 10: Global Market Value (USD Billion) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Billion) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Biopsy Equipment Market Value (USD Billion) By Region

Figure 15: Global Biopsy Equipment Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Billion) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Billion) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Biopsy Equipment Market Value (USD Billion) By Region

Figure 23: Global Biopsy Equipment Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

83 items

Table 1: Market Segmentation Analysis

Table 2: Global Biopsy Equipment Revenue (USD Billion) And Cagr (%) By Application (2020-2032)

Table 3: Global Biopsy Equipment Revenue (USD Billion) And Cagr (%) By Types (2020-2032)

Table 4: Global Biopsy Equipment Revenue (USD Billion) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Billion) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Billion) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Biopsy Equipment Market Value (USD Billion) By Region

Table 10: Global Biopsy Equipment Market Share (%) By Region

Table 11: North America Market Value (USD Billion) (2020-2024) By Country

Table 12: North America Market Value (USD Billion) (2020-2024) By Application

Table 13: North America Market Value (USD Billion) (2020-2024) By Types

Table 14: Europe Market Value (USD Billion) (2020-2024) By Country

Table 15: Europe Market Value (USD Billion) (2020-2024) By Application

Table 16: Europe Market Value (USD Billion) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Billion) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Billion) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Billion) (2020-2024) By Types

Table 20: South America Market Value (USD Billion) (2020-2024) By Country

Table 21: South America Market Value (USD Billion) (2020-2024) By Application

Table 22: South America Market Value (USD Billion) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Billion) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Billion) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Billion) (2020-2024) By Types

Table 26: Global Biopsy Equipment Market Revenue (USD Billion) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Biopsy Equipment Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Biopsy Equipment Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: BD Basic Information And Sales Area

Table 31: BD. Products Portfolio

Table 32: Medtronic Basic Information And Sales Area

Table 33: Medtronic. Products Portfolio

Table 34: Boston Scientific Basic Information And Sales Area

Table 35: Boston Scientific. Products Portfolio

Table 36: B. Braun Melsungen Basic Information And Sales Area

Table 37: B. Braun Melsungen. Products Portfolio

Table 38: Invivo Basic Information And Sales Area

Table 39: Invivo. Products Portfolio

Table 40: Hologic Basic Information And Sales Area

Table 41: Hologic. Products Portfolio

Table 42: UroMed Basic Information And Sales Area

Table 43: UroMed. Products Portfolio

Table 44: Cook Medical Basic Information And Sales Area

Table 45: Cook Medical. Products Portfolio

Table 46: Argon Medical Devices Basic Information And Sales Area

Table 47: Argon Medical Devices. Products Portfolio

Table 48: Sterylab Basic Information And Sales Area

Table 49: Sterylab. Products Portfolio

Table 50: INRAD Basic Information And Sales Area

Table 51: INRAD. Products Portfolio

Table 52: Merit Medical Systems Basic Information And Sales Area

Table 53: Merit Medical Systems. Products Portfolio

Table 54: CooperSurgical Basic Information And Sales Area

Table 55: CooperSurgical. Products Portfolio

Table 56: DTR Medical Basic Information And Sales Area

Table 57: DTR Medical. Products Portfolio

Table 58: GerMedUSA Inc Basic Information And Sales Area

Table 59: GerMedUSA Inc. Products Portfolio

Table 60: Global Market Value (USD Billion) (2025-2032) By Application

Table 61: Global Market Share (%) By Application (2032)

Table 62: Global Market Value (USD Billion) (2025-2032) By Types

Table 63: Global Market Share (%) By Types (2032)

Table 64: Global Biopsy Equipment Market Value (USD Billion) By Region

Table 65: Global Biopsy Equipment Market Share (%) By Region (2025-2032)

Table 66: North America Market Value (USD Billion) (2025-2032) By Country

Table 67: North America Market Value (USD Billion) (2025-2032) By Application

Table 68: North America Market Value (USD Billion) (2025-2032) By Types

Table 69: Europe Market Value (USD Billion) (2025-2032) By Country

Table 70: Europe Market Value (USD Billion) (2025-2032) By Application

Table 71: Europe Market Value (USD Billion) (2025-2032) By Types

Table 72: Asia Pacific Market Value (USD Billion) (2025-2032) By Country

Table 73: Asia Pacific Market Value (USD Billion) (2025-2032) By Application

Table 74: Asia Pacific Market Value (USD Billion) (2025-2032) By Types

Table 75: South America Market Value (USD Billion) (2025-2032) By Country

Table 76: South America Market Value (USD Billion) (2025-2032) By Application

Table 77: South America Market Value (USD Billion) (2025-2032) By Types

Table 78: Middle East & Africa Market Value (USD Billion) (2025-2032) By Country

Table 79: Middle East & Africa Market Value (USD Billion) (2025-2032) By Application

Table 80: Middle East & Africa Market Value (USD Billion) (2025-2032) By Types

Table 81: Research Programs/Design For This Report

Table 82: Key Data Information From Secondary Sources

Table 83: Key Data Information From Primary Sources

FAQs

1. What is the current Biopsy Equipment market size?

The Biopsy Equipment market size was valued at approximately USD 1.3 billion in 2023, reflecting steady demand across oncology, gastroenterology and interventional radiology. This figure incorporates both disposable and reusable devices and sets a baseline for the upcoming growth trajectory.

2. How is the market expected to grow over the next decade?

The market is projected to expand at a compound annual growth rate of 5.8 % from 2024 to 2034, reaching roughly USD 2.2 billion by the end of the forecast period. This growth reflects rising cancer incidence and expanding minimally invasive procedures.

3. Which factors are driving the expansion of the Biopsy Equipment market?

Key drivers include increasing global cancer prevalence, growing adoption of image‑guided biopsies, aging populations, and reimbursement reforms that favor early diagnosis. Additionally, advancements in needle design and real‑time imaging integration boost procedural efficiency, further stimulating market demand.

4. What are the main challenges limiting market growth?

Challenges stem from high upfront costs of advanced biopsy systems, stringent sterilization requirements, and limited reimbursement in emerging economies. Moreover, procedural complications and a shortage of trained personnel can deter adoption, especially for high‑precision robotic platforms.

5. Which regions are leading in terms of revenue and adoption?

North America remains the revenue leader, driven by robust healthcare infrastructure and high procedure volumes. Europe follows with strong adoption of minimally invasive techniques, while Asia‑Pacific exhibits the fastest growth rate due to expanding oncology services and rising middle‑class populations.

6. Who are the top companies competing in this market?

Leading players include Medtronic, Johnson & Johnson (Ethicon), Boston Scientific, Olympus Corporation, and C. R. Bard (now part of BD). These firms compete on product innovation, global distribution networks, and strategic acquisitions to strengthen their positions in the Biopsy Equipment market.

7. What future opportunities are emerging for manufacturers?

Future opportunities arise from personalized medicine, demand for on‑site pathology, and integration of AI‑driven decision support. Companies can also explore disposable micro‑needle arrays and tele‑biopsy platforms, which address infection control concerns and expand access in remote or underserved regions.

8. How are technological advancements reshaping the market?

Technological impact includes the shift to robotic‑assisted biopsy, real‑time OCT and elastography imaging, and smart needle sensors that provide tactile feedback. These innovations improve diagnostic accuracy, reduce procedure time, and create new revenue streams for equipment manufacturers.

9. What regulatory trends are influencing market dynamics?

Regulatory landscape is shaped by FDA 510(k) clearances in the U.S., CE marking in Europe, and emerging medical device regulations in Asia. Compliance demands rigorous clinical validation, post‑market surveillance, and alignment with evolving standards for patient safety and data security.

Contact for Full Report

Loading report content...

Biopsy Equipment Industry Size, Share & Growth Forecast 2033

Market Snapshot

Biopsy Equipment Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Biopsy Equipment Segmentation

Biopsy Equipment Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Biopsy Equipment market size?

2. How is the market expected to grow over the next decade?

3. Which factors are driving the expansion of the Biopsy Equipment market?

4. What are the main challenges limiting market growth?

5. Which regions are leading in terms of revenue and adoption?

6. Who are the top companies competing in this market?

7. What future opportunities are emerging for manufacturers?

8. How are technological advancements reshaping the market?

9. What regulatory trends are influencing market dynamics?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Biopsy Equipment Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Biopsy Equipment Segmentation

Biopsy Equipment Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Biopsy Equipment market size?

2. How is the market expected to grow over the next decade?

3. Which factors are driving the expansion of the Biopsy Equipment market?

4. What are the main challenges limiting market growth?

5. Which regions are leading in terms of revenue and adoption?

6. Who are the top companies competing in this market?

7. What future opportunities are emerging for manufacturers?

8. How are technological advancements reshaping the market?

9. What regulatory trends are influencing market dynamics?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation